• MJHLS Brand Logo

© 2020 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.

Insights

Challenges and Opportunities for Patients With HIV During COVID-19

The Impact of COVID-19 on the HIV Community
The Impact of COVID-19 on the HIV Community

Current and Future Treatments for the Management of Myelodysplastic Syndrome

An Overview of Myelodysplastic Syndrome
An Overview of Myelodysplastic Syndrome
Understanding Myelodysplastic Syndrome's Nature as Cancer
Understanding Myelodysplastic Syndrome's Nature as Cancer
Myelodysplastic Syndrome: Diagnosis and Risk Stratification
Myelodysplastic Syndrome: Diagnosis and Risk Stratification
Clinical Burden of Myelodysplastic Syndrome
Clinical Burden of Myelodysplastic Syndrome
Economic Burden of Myelodysplastic Syndrome
Economic Burden of Myelodysplastic Syndrome
Myelodysplastic Syndrome: Goals of Therapy
Myelodysplastic Syndrome: Goals of Therapy
MDS Management: Use of Bone Marrow Transplantation
MDS Management: Use of Bone Marrow Transplantation
Therapies and Treatment Regimens for MDS
Therapies and Treatment Regimens for MDS
Hypomethylating Agents in MDS Management
Hypomethylating Agents in MDS Management
MDS Management: Use of Transfusion Alongside HMAs
MDS Management: Use of Transfusion Alongside HMAs
Potential Complications of Transfusions in MDS Management
Potential Complications of Transfusions in MDS Management
MDS Management: Challenges With Chemotherapy
MDS Management: Challenges With Chemotherapy
MDS Management: ASCERTAIN Equivalence Study
MDS Management: ASCERTAIN Equivalence Study
Oral HMAs in MDS Management: Adherence and Accessibility
Oral HMAs in MDS Management: Adherence and Accessibility
Oral HMAs in MDS: Personal Experience and Future Directions
Oral HMAs in MDS: Personal Experience and Future Directions
MDS: Access to Care and Other Ongoing Challenges
MDS: Access to Care and Other Ongoing Challenges
Practical Advice for Managing Myelodysplastic Syndrome
Practical Advice for Managing Myelodysplastic Syndrome

Employer Opportunities With Biosimilars

Overview and Manufacturing of Biologics
Overview and Manufacturing of Biologics
Differentiating Biosimilars From Generic Drugs
Differentiating Biosimilars From Generic Drugs
Value of Biosimilars to Employers
Value of Biosimilars to Employers
Promoting Biosimilar Uptake
Promoting Biosimilar Uptake
NAHPC Biosimilar Uptake Action Steps for Employers: Step 1
NAHPC Biosimilar Uptake Action Steps for Employers: Step 1
NAHPC Biosimilar Uptake Action Steps 2 and 3
NAHPC Biosimilar Uptake Action Steps 2 and 3
NAHPC Biosimilar Uptake Action Step 4
NAHPC Biosimilar Uptake Action Step 4

Understanding the Subpopulations of Pulmonary Hypertension

An Overview of PH and PAH
An Overview of PH and PAH
Considering the Economic Burden of PH and PAH
Considering the Economic Burden of PH and PAH
Identifying Subpopulations of PH and PAH
Identifying Subpopulations of PH and PAH
PH and PAH: An Overview of Treatment Options and Coverage
PH and PAH: An Overview of Treatment Options and Coverage
PH and PAH: Mechanisms of Action of Common Treatment Pathway
PH and PAH: Mechanisms of Action of Common Treatment Pathway
Oral, Parenteral, and Inhaled Agents in PH and PAH
Oral, Parenteral, and Inhaled Agents in PH and PAH
Identifying Connective Tissue Disease–Associated PAH
Identifying Connective Tissue Disease–Associated PAH
CTD-PAH: Overview of Treatment Strategies
CTD-PAH: Overview of Treatment Strategies
Considering Therapy Based on PH and PAH Subpopulations
Considering Therapy Based on PH and PAH Subpopulations
Treatment for PH and PAH: Factors That Inform Coverage
Treatment for PH and PAH: Factors That Inform Coverage
CTD-PAH: Adjusting Treatment Based on Patient Factors
CTD-PAH: Adjusting Treatment Based on Patient Factors
Identifying Portopulmonary Hypertension
Identifying Portopulmonary Hypertension
POPH: Challenges and Treatment Options
POPH: Challenges and Treatment Options
Complexity of Chronic Thromboembolic Pulmonary Hypertension
Complexity of Chronic Thromboembolic Pulmonary Hypertension
Optimal Management of CTEPH
Optimal Management of CTEPH
PH and PAH: Where and From Whom Are Patients Receiving Care
PH and PAH: Where and From Whom Are Patients Receiving Care
PH and PAH: Care Coordination From the Payer Perspective
PH and PAH: Care Coordination From the Payer Perspective
PH and PAH: Defining Barriers and Gaps in Care
PH and PAH: Defining Barriers and Gaps in Care
The Evolving Treatment Landscape of PH and PAH
The Evolving Treatment Landscape of PH and PAH

Migraine Management: The Business Case

Understanding Migraines From the Employer Perspective
Understanding Migraines From the Employer Perspective
Economic Impact of Migraines
Economic Impact of Migraines
Patient and Social Impact of Migraines in the Workplace
Patient and Social Impact of Migraines in the Workplace
Employer Accommodations for Migraines
Employer Accommodations for Migraines
Addressing Migraine Through Benefit Design
Addressing Migraine Through Benefit Design
Self-Insured Health Systems for Employees With Migraines
Self-Insured Health Systems for Employees With Migraines
Educational Organizations and Migraine Management
Educational Organizations and Migraine Management
Wellness Programs for Employees With Migraines
Wellness Programs for Employees With Migraines
Migraine Misconceptions and Final Thoughts
Migraine Misconceptions and Final Thoughts

Management of Advanced Fibrosis due to Non-Alcoholic SteotoHepatitis

Advanced Fibrosis Due to NASH
Advanced Fibrosis Due to NASH
NASH and Advanced Fibrosis: Risk Factors
NASH and Advanced Fibrosis: Risk Factors
Methods to Diagnose Advanced Fibrosis Due to NASH
Methods to Diagnose Advanced Fibrosis Due to NASH
Liver Biopsy in Advanced Fibrosis Due to NASH
Liver Biopsy in Advanced Fibrosis Due to NASH
Noninvasive Testing in Advanced Fibrosis Due to NASH
Noninvasive Testing in Advanced Fibrosis Due to NASH
The Progressive Nature of NASH
The Progressive Nature of NASH
Advanced Fibrosis in NASH: Patient Management
Advanced Fibrosis in NASH: Patient Management
Burden of Advanced Fibrosis Caused by NASH
Burden of Advanced Fibrosis Caused by NASH
Reversing Advanced Fibrosis Caused by NASH
Reversing Advanced Fibrosis Caused by NASH
Lifestyle Modification in Advanced Fibrosis From NASH
Lifestyle Modification in Advanced Fibrosis From NASH
Drug Therapy & Liver Transplant for Advanced Fibrosis/NASH
Drug Therapy & Liver Transplant for Advanced Fibrosis/NASH
Addressing Barriers in Advanced Fibrosis/NASH
Addressing Barriers in Advanced Fibrosis/NASH